Other transitory neonatal endocrine disorders (P72) ICD-10-CM
The P72 code range covers other transitory neonatal endocrine disorders with 6 ICD-10-CM diagnosis codes. 5 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Codes in the P72 Range 6 codes · 5 billable
- P72 Other transitory neonatal endocrine disordersNon-billable
- P72.0 Neonatal goiter, not elsewhere classified
- P72.1 Transitory neonatal hyperthyroidism
- P72.2 Other transitory neonatal disorders of thyroid function, not elsewhere classified
- P72.8 Other specified transitory neonatal endocrine disorders
- P72.9 Transitory neonatal endocrine disorder, unspecified
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the P72 range.
Congenital Hypothyroidism
A condition in infancy or early childhood due to an in-utero deficiency of THYROID HORMONES that can be caused by genetic or environmental factors, such as thyroid dysgenesis or HYPOTHYROIDISM in infants of mothers treated with THIOURACIL during pregnancy. Endemic cretinism is the result of iodine deficiency. Clinical symptoms include severe MENTAL RETARDATION, impaired skeletal development, short stature, and MYXEDEMA.
Goiter
Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency (HYPOTHYROIDISM), or hormone overproduction (HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic (GOITER, ENDEMIC).
Goiter, Endemic
A form of IODINE deficiency disorders characterized by an enlargement of the THYROID GLAND in a significantly large fraction of a POPULATION GROUP. Endemic goiter is common in mountainous and iodine-deficient areas of the world where the DIET contains insufficient amount of iodine.
Goiter, Nodular
An enlarged THYROID GLAND containing multiple nodules (THYROID NODULE), usually resulting from recurrent thyroid HYPERPLASIA and involution over many years to produce the irregular enlargement. Multinodular goiters may be nontoxic or may induce THYROTOXICOSIS.
Goiter, Substernal
An enlarged THYROID GLAND with at least 50% of the gland situated behind the STERNUM. It is an unusual presentation of an intrathoracic goiter. Substernal goiters frequently cause compression on the TRACHEA leading to deviation, narrowing, and respiratory symptoms.
Graves Disease
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
Hyperthyroidism
Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.
Hypothyroidism
A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.
Lingual Goiter
Pathological enlargement of the LINGUAL THYROID, ectopic thyroid tissue at the base of the TONGUE. It may cause upper AIRWAY OBSTRUCTION; DYSPHAGIA; or HYPOTHYROIDISM symptoms.
Thyrotoxicosis
A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.
About the P72 Code Range
ICD-10 code section P72 covers other transitory neonatal endocrine disorders, which are temporary hormonal conditions occurring in newborns. These codes help identify specific short-term thyroid and endocrine dysfunctions that appear around birth.
This section includes codes like P72.0 for neonatal goiter (a mass or enlargement of the thyroid gland in newborns), and P72.1 which addresses transitory neonatal hyperthyroidism, also known as neonatal thyrotoxicosis or neonatal Graves' disease. Code P72.2 covers various transitory neonatal hypothyroidism conditions, including temporary or acquired low thyroid hormone levels in infants, sometimes caused by maternal factors or iodine exposure. P72.8 includes other specific transient endocrine issues in newborns, such as neonatal hyperparathyroidism and transient neonatal hypoglycemia. Finally, P72.9 is used for unspecified transient endocrine disorders when the condition lacks a precise classification. Using these detailed ICD-10 codes ensures accurate documentation of newborn endocrine disorders for clinical and billing purposes and helps distinguish each condition by its unique presentation and course.
Questions About This Page
How many billable codes are in the P72 range?
Of the 6 codes in this range, 5 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the P72 range classify?
The range classifies other transitory neonatal endocrine disorders. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
